Abdominal Pain
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormal form of the vertebral bodies
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormal hemoglobin finding
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormal megakaryocyte morphology
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormal platelet morphology
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Acute Erythroblastic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
All FAB M6 and M7 and trilineal leukaemias expressed mRNAs for alpha-globin, glycoprotein IIb (GpIIb), erythropoietin receptor (Epo-R) and thrombopoietin receptor (c-mpl), but not for myeloperoxidase (MPO) which in contrast was expressed in the other FAB-subtype leukaemias.
|
9753066 |
1998 |
Acute leukemia
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
These mutations include JAK2, CALR and MPL mutations as the main disease drivers, mutations driving clonal expansion, and mutations that contribute to progression of chronic MPNs to myelodysplasia and acute leukemia.
|
31741139 |
2020 |
Acute leukemia
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
Acute lymphocytic leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Retrospective molecular studies detected a MPL W515S homozygous mutation in both the initial and remission marrows for B-ALL, at 30-40% and 80% dosage effect, respectively.
|
25453399 |
2015 |
Acute Megakaryocytic Leukemias
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results establish that concomitant activation of RBPJ (Notch signaling) and MPL (cytokine signaling) transforms cells of the megakaryocytic lineage and suggest that specific targeting of these pathways could be of therapeutic value for human AMKL.
|
19287095 |
2009 |
Acute panmyelosis with myelofibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In total, 199 patients with MPN (54 primary myelofibrosis [PMF], 79 essential thrombocythemia [ET], 58 polycythemia vera [PV], and eight MPN-unclassifiable [MPN-U]) and 4 patients with acute panmyelosis with myelofibrosis (APMF) were retrospectively subjected to Sanger sequencing for CALR, JAK2, and MPL.
|
25873496 |
2015 |
Acute Promyelocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, CD110 and CD33 reactivity may be useful to distinguish APL from NPM-mutated AML with CD15, CD34 and HLA-DR negativity.
|
21812014 |
2012 |
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The thrombopoietin receptor agonist romiplostim improves exposure to chemotherapy in patients with glioblastoma experiencing temozolomide-induced thrombocytopenia.
|
31586022 |
2019 |
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The magnetic PLGA/MPLs nanosphere may be another option for treatment of glioblastoma.
|
22961067 |
2012 |
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In particular, besides some cytokines like IFN-α and IL-2, several Toll-like receptor (TLR) agonists like BCG, MPL, and imiquimod are also licensed to be used in patients with several malignancies nowadays, and the first artificial small noncoding RNA (microRNA) mimic, MXR34, has entered phase I clinical study against liver cancer, implying their potential application in cancer therapy.
|
27240457 |
2016 |
Adult Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of thrombopoietin and thrombopoietin receptor MPL in human leukemia-lymphoma and solid tumor cell lines.
|
8960108 |
1996 |
Adult Medulloblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.
|
19270706 |
2009 |
Adult Myelodysplastic Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The gene for the thrombopoietin receptor, c-mpl, has been shown to be overexpressed at the mRNA level in acute myeloid leukemia (AML) and myelodysplastic syndrome.
|
9933137 |
1999 |
Adult Myelodysplastic Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We report a patient with a JAK2 V617F-negative myeloproliferative/myelodysplastic syndrome who had abnormal megakaryocytic pSTAT5 expression and a MPL W515L mutation.
|
18479730 |
2008 |
Amaurosis Fugax
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Amegakaryocytic thrombocytopenia
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
Amegakaryocytic thrombocytopenia
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
To our knowledge, this is the first report that describes a case of amegakaryocytic thrombocytopenia that is not caused by a mutation in MPL and demonstrates the severe impairment of GPVI expression on platelets.
|
18194481 |
2008 |
Anemia
|
0.130 |
Biomarker
|
disease |
HPO |
|
|
|
Anemia
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Congenital amegakaryocytic thrombocytopenia (CAMT) is caused by the loss of thrombopoietin receptor-mediated (MPL-mediated) signaling, which causes severe pancytopenia leading to bone marrow failure with onset of thrombocytopenia and anemia prior to leukopenia.
|
23908116 |
2013 |
Anemia
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Median mutation levels in pretreatment ET samples were significantly higher for MPL-mutated cases (60%) than for JAK2-mutated cases (24%; P=0.01), as was presentation with anemia.
|
20113830 |
2010 |